JP2010533169A - ヤシの葉からの抽出物およびその製造方法 - Google Patents
ヤシの葉からの抽出物およびその製造方法 Download PDFInfo
- Publication number
- JP2010533169A JP2010533169A JP2010515987A JP2010515987A JP2010533169A JP 2010533169 A JP2010533169 A JP 2010533169A JP 2010515987 A JP2010515987 A JP 2010515987A JP 2010515987 A JP2010515987 A JP 2010515987A JP 2010533169 A JP2010533169 A JP 2010533169A
- Authority
- JP
- Japan
- Prior art keywords
- palm
- extract
- leaves
- polar
- plant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims description 64
- 238000004519 manufacturing process Methods 0.000 title description 2
- 241001133760 Acoelorraphe Species 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 29
- 239000002798 polar solvent Substances 0.000 claims abstract description 18
- 239000012676 herbal extract Substances 0.000 claims abstract description 9
- 238000000605 extraction Methods 0.000 claims description 50
- 239000002904 solvent Substances 0.000 claims description 28
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 18
- 241000196324 Embryophyta Species 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 13
- 235000001950 Elaeis guineensis Nutrition 0.000 claims description 12
- 241000512897 Elaeis Species 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 230000036996 cardiovascular health Effects 0.000 claims description 9
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 8
- 235000018060 Elaeis melanococca Nutrition 0.000 claims description 8
- 235000010659 Phoenix dactylifera Nutrition 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241001608549 Elaeis oleifera Species 0.000 claims description 7
- 241000233805 Phoenix Species 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 6
- 241000233788 Arecaceae Species 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 3
- 241000737241 Cocos Species 0.000 claims 3
- 238000004140 cleaning Methods 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 62
- 241001465754 Metazoa Species 0.000 description 47
- 235000012000 cholesterol Nutrition 0.000 description 29
- 241000700159 Rattus Species 0.000 description 22
- 235000005911 diet Nutrition 0.000 description 22
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 21
- 230000037213 diet Effects 0.000 description 21
- 206010020772 Hypertension Diseases 0.000 description 20
- 239000004615 ingredient Substances 0.000 description 19
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 150000002989 phenols Chemical class 0.000 description 13
- 230000036772 blood pressure Effects 0.000 description 12
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 12
- 229930003935 flavonoid Natural products 0.000 description 12
- 235000017173 flavonoids Nutrition 0.000 description 12
- 150000002215 flavonoids Chemical class 0.000 description 12
- 229960000830 captopril Drugs 0.000 description 11
- 230000001631 hypertensive effect Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 206010003210 Arteriosclerosis Diseases 0.000 description 7
- 108010023302 HDL Cholesterol Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 6
- 230000003579 anti-obesity Effects 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940118019 malondialdehyde Drugs 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 244000060011 Cocos nucifera Species 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000003276 anti-hypertensive effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 210000000748 cardiovascular system Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- JSUVCAQGWVUMPD-QXUQJYLISA-N Arjuna Natural products O([C@H]([C@@H](O)C=O)[C@H]1[C@H](O)COC(=O)c2c(c(O)c(O)c(O)c2)-c2c(O)c(O)c3OC(=O)c4c(c(O)c(O)c5OC(=O)c2c3-c45)-c2c(O)c(O)c(O)cc2C(=O)O1)C(=O)c1cc(O)c(O)c(O)c1 JSUVCAQGWVUMPD-QXUQJYLISA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000015092 herbal tea Nutrition 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000002669 organ and tissue protective effect Effects 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 244000127993 Elaeis melanococca Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 230000000923 atherogenic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 230000005800 cardiovascular problem Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 244000104275 Phoenix dactylifera Species 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 235000020344 instant tea Nutrition 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 230000002883 vasorelaxation effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
【選択図】図1
Description
本発明の更に他の実施形態において、ヤシ科の植物の葉は、好適にはギニアアブラヤシ(Elaeis guineensis)、アメリカアブラヤシ(Elaeis oleifera)、ナツメヤシ(Phoenix dactylifera)およびCocos nucifera(ココヤシ)のいずれか1つからまたは組み合わせから得られるが、これらに限定されない。
実施された実験から、この実施形態に採用された抽出物が抗高血圧、抗酸化的、抗動脈硬化、抗高コレステロール、抗高脂血症、抗肥満、血管弛緩および類似の作用を示すことは明らかである。更に、ヤシ科の植物は、ギニアアブラヤシ、アメリカアブラヤシ、ナツメヤシおよびココヤシのいずれか1つまたは組み合わせであるが、これらに限定されない。
油ヤシの葉を集め、清浄、水洗および小片に切断し、および40℃で一晩オーブン乾燥した。乾燥物をブレンダーを用いて粉砕し、抽出物アルコール(1:10v/v)で3回およびアセトンまたはクロロホルムおよびアルコールの混合物で3回抽出した。ポリフェノール抽出の媒体として他の溶媒を用い得る。これは、固体マトリックス(植物組織)から液体マトリックス(溶媒)を用いて拡散により可溶性フェノール化合物を分離するために設計されたプロセスである。フラボン、フラボノールおよびカテキンの抽出において、アルコール、クロロホルムおよびアセトンは、良好な収量を与えた。抽出は数回行った。合わせた抽出物を40℃で真空乾燥し、使用まで貯蔵した。
高コレステロール食(C)で飼育した動物は、血漿TCが6週間中に67%および12週間中に83%だけ増加し、これは正常な対照動物(N)よりも顕著に高かった。ヤシの葉抽出物およびヤシの葉機能性成分で補給された高コレステロール食で飼育した動物は、高コレステロール食(C)単独で飼育した動物と比べて低い血漿TC価(61%だけ低い)を示した。
<表1>
*−p<0.05vsN対照、#−p<0.05vsC対照
表2は、高血圧動物(SHR)の赤血球SOD、GSH−Px5およびCAT活性が、対照正常血圧動物(N)と比べて顕著に増加したことを示し、動物の増加した酸化状態を示している。ヤシの葉抽出物およびヤシの葉機能性成分で補給された高血圧動物(SHR)、(SHR+OPLE)は、顕著な減少した赤血球SOD、GSH−Px、およびCAT活性を示し、それを正常血圧動物の正常濃度近くに戻す。SOD、GSH−Px、およびCATは、酸化的ストレスに対する抗酸化酵素防御の最前線であり、反応性酸素を過酸化水素および水に変換する。SOD、GSH−Px5およびCATの低下した活性は、油ヤシの葉抽出物で補給された高血圧動物における減少した酸化的ストレスを示す。同様な結果が、高血圧によって最も普通に影響される臓器、即ち腎臓、心臓および脳で観察される。
<表2>
対照=正常血圧動物;OPLE=ヤシの葉抽出物で処理された正常血圧動物;カプトプリル=カプトプリルで処理された正常血圧動物;SHR=自然発生/遺伝的高血圧動物;SHR+OPLE=OPLEで処理されたSHR;SHR+カプトプリル=カプトプリルで処理されたSHR*P<0.05vs正常血圧対照;#P<0.05vs高血圧SHR
<表3>
対照=正常血圧動物;OPLE=ヤシの葉抽出物で処理された正常血圧動物;カプトプリル=カプトプリルで処理された正常血圧動物;SHR=自然発生/遺伝的高血圧動物;SHR+OPLE=OPLEで処理されたSHR;SHR+カプトプリル=カプトプリルで処理されたSHR*P<0.05vs正常血圧対照;#P<0.05vs高血圧SHR
血圧
図2は、L−NAME誘発高血圧群における血圧のデータを纏める。オリジナルのヤシの葉抽出物(OPLE)の同時投与によって顕著に軽減したL−NAME誘発時間依存性血圧上昇の治療。
収縮期血圧(SBP)は、L−NAME+OPLE動物で週1直後から試験を通して低く、OPLEで治療されていない動物における値に対して、正常範囲(<140mmHg)内に留まった。軽減は、L−NAME+抗高血圧薬カプトプリルおよび対照正常血圧動物のそれらと類似していた。
しかし、収縮期血圧は、OPLEで補給された正常血圧動物で低下しなかった。(図2)
SHR群はすべて、対照に比べて顕著に低い体重を有した。腎臓/体重は、すべての群で同様であった。L−NAME+OPLEラットにおける心臓/体重値は、L−NAMEラットのそれらと顕著に異ならなかった。しかし、L−NAME+カプトプリルラットは、L−NAMEに比べ心臓/体重比は低かった。SHRおよびSHR+カプトプリルの心臓/体重比は、対照ラットのそれより顕著に高かったが、SHR+OPLEラットにおいて、その比は、SHRのそれより顕著に低く、対照ラットと類似していた。
<表4>
L−NAME=Nω−ニトロ−L−アルギニンメチルエステル;データは、平均±SEMで示す。
*P<0.05vsL−NAME誘発高血圧ラット
#P<0.05vs正常血圧対照
+P<0.05vsSHR(自然発生/遺伝的高血圧ラット)
表5に実験ラットの血清で測定した酸化窒素値を纏める。週6において、L−NAMEおよびL−NAME+OPLEラットで、対照ラッに比べ酸化窒素(NO)濃度は顕著に減少した。NOは、L−NAME+OPLEラットで、L−NAMEラットの値と比べて、僅かに増加した。しかし、8週までに、血清NOは、L−NAMEおよびL−NAME+OPLEラットの両方で対照ラットと類似した濃度に戻り、試験の終了まで維持された。L−NAME+OPLEラットで、L−NAMEラットと比べてNOの部分的な増加があるが、顕著でなかった。SHR+OPLEラットで、SHRおよび対照ラットに比べて酸化窒素濃度が顕著に増加した。本試験の終了までに、SHR+カプトプリル群だけが、対照ラットに対して顕著に高い酸化窒素濃度を有した。
<表5>
SHR=自然発生高血圧ラット;+P<0.05vs対照;*P<0.05vsL−NAME;#P<0.05vsSHR
Claims (12)
- ヤシ科の植物の葉からの極性抽出溶媒を用いた抽出物を含む、個体の心血管系の健康管理を促進する調理済み組成物。
- 抽出物が濃縮された形で調製される、請求項1に記載の調理済み組成物。
- ヤシ科の植物がギニアアブラヤシ、アメリカアブラヤシ、ナツメヤシおよびココヤシのいずれか1つまたは組み合わせである、請求項1および2に記載の調理済み組成物。
- 極性抽出溶媒が、水、アルコール、アセトン、クロロホルムおよびそのいずれかの組み合わせからなる群から選ばれる、請求項1および2に記載の調理済み組成物。
- ヤシ科の植物の葉からの極性抽出溶媒を用いた抽出物の有効量を対象に経口投与する段階を含む、対象における心血管系の健康管理を促進する方法。
- ヤシ科の植物が、ギニアアブラヤシ、アメリカアブラヤシ、ナツメヤシおよびココヤシのいずれか1つまたは組み合わせである、請求項5に記載の方法。
- 極性溶媒が、水、アルコール、アセトンおよびクロロホルムのいずれか1つまたは組み合わせである、請求項5に記載の方法。
- 下記の段階:
(a)ヤシ科の植物からの葉の前処理;
(b)極性溶媒を用いる前処理葉の抽出;
(c)使用した極性溶媒からの前処理葉の除去;および
(d)使用した極性溶媒を濃縮して薬草抽出物を得ること
を含む薬草抽出物の調製方法。 - ヤシ科の植物がギニアアブラヤシ、アメリカアブラヤシ、ナツメヤシおよびココヤシからなる群から選ばれる、請求項8に記載の方法。
- 極性溶媒が水、アルコール、アセトンおよびクロロホルムのいずれか1つまたは組み合わせである、請求項8に記載の方法。
- 前処理が、葉の清浄、葉の乾燥および葉の粉砕のいずれか1つまたは組み合わせである、請求項8に記載の方法。
- 乾燥葉の極性抽出溶媒に対する比が、1−3:6−10(w/v)である、請求項8に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MYPI20071111A MY164863A (en) | 2007-07-11 | 2007-07-11 | Extract from palm leaves and a method for producing the same |
PCT/MY2008/000065 WO2009008697A1 (en) | 2007-07-11 | 2008-07-09 | Extract from palm leaves and a method for producing the same |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013167153A Division JP2014001222A (ja) | 2007-07-11 | 2013-08-09 | ヤシの葉からの抽出物およびその製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2010533169A true JP2010533169A (ja) | 2010-10-21 |
Family
ID=40228773
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010515987A Pending JP2010533169A (ja) | 2007-07-11 | 2008-07-09 | ヤシの葉からの抽出物およびその製造方法 |
JP2013167153A Pending JP2014001222A (ja) | 2007-07-11 | 2013-08-09 | ヤシの葉からの抽出物およびその製造方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013167153A Pending JP2014001222A (ja) | 2007-07-11 | 2013-08-09 | ヤシの葉からの抽出物およびその製造方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8808760B2 (ja) |
EP (1) | EP2170105A4 (ja) |
JP (2) | JP2010533169A (ja) |
CN (1) | CN101742928A (ja) |
AU (1) | AU2008273073B2 (ja) |
MY (1) | MY164863A (ja) |
WO (1) | WO2009008697A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY157650A (en) * | 2008-03-06 | 2016-07-15 | Nova Lab Sdn Bhd | Extract from oil palm leaves comprising phenolic acids |
US20110189222A1 (en) * | 2008-09-30 | 2011-08-04 | Suhaila Mohamed | Composition for wound healing |
US20120276225A1 (en) * | 2009-03-24 | 2012-11-01 | Universiti Putra Malaysia | Phytoestrogenic nutraceutical composition from palm leaf extract |
EP2411033B1 (en) | 2009-03-24 | 2015-03-04 | Universiti Putra Malaysia | Anti-diabetic nutraceutical composition from palm leaf extract |
MY173655A (en) * | 2009-06-09 | 2020-02-14 | Malaysian Palm Oil Board | Composition and method for improving vascular health |
MY185582A (en) * | 2010-01-07 | 2021-05-24 | Malaysian Palm Oil Board | Anti-obesity and anti-dyslipidemic effects of oil palm phenolics in preventing atheroslerosis and cardiovascular disease |
CN103610866B (zh) * | 2013-11-25 | 2015-07-29 | 济南伟传信息技术有限公司 | 一种治疗高血压病的中药 |
US20160278416A1 (en) * | 2015-03-24 | 2016-09-29 | Malaysian Palm Oil Board (Mpob) | Methods for producing water soluble oil palm leaf powder and concentrate |
CN105595412B (zh) * | 2016-01-29 | 2017-06-13 | 广西中烟工业有限责任公司 | 一种桄榔粉提取物的制备方法及其在卷烟中的应用 |
CH715443B1 (fr) * | 2018-10-11 | 2020-12-30 | Mytamar Gmbh | Extrait purifié et concentré de polyphénols issu des fruits du palmier dattier Phoenix dactylifera. |
US11332439B2 (en) | 2020-10-14 | 2022-05-17 | United Arab Emirates University | Anthocyanin complex synthesized from date palm leaf extract |
CN113967956A (zh) * | 2021-11-04 | 2022-01-25 | 程栋 | 一种棕榈科叶子新材料及其制造方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH622435A5 (ja) * | 1978-01-03 | 1981-04-15 | Chemap Ag | |
JPH09206043A (ja) | 1996-02-06 | 1997-08-12 | Nippon Kanpo Kenkyusho:Kk | シュロ茶 |
BG62593B1 (bg) | 1996-05-17 | 2000-03-31 | Диетична храна с кардиотонично, съдоукрепващо, антилипемичнои тонизиращо действие | |
WO2005070442A1 (en) * | 2003-12-22 | 2005-08-04 | Council Of Scientific & Industrial Research | A synergistic composition for treating hyperlipidemia |
US20070036821A1 (en) * | 2004-03-05 | 2007-02-15 | Daniels Bruce A | Seaweed extract composition for retardation of cardiovascular disorders and preservation of healthy cardiovascular function |
MX2007010322A (es) | 2005-02-23 | 2009-03-02 | Avestha Gengraine Tech Pvt Ltd | Extractos de planta y metodos y usos de los mismos. |
-
2007
- 2007-07-11 MY MYPI20071111A patent/MY164863A/en unknown
-
2008
- 2008-07-09 WO PCT/MY2008/000065 patent/WO2009008697A1/en active Application Filing
- 2008-07-09 EP EP08778988A patent/EP2170105A4/en not_active Ceased
- 2008-07-09 US US12/668,311 patent/US8808760B2/en not_active Expired - Fee Related
- 2008-07-09 CN CN200880024078A patent/CN101742928A/zh active Pending
- 2008-07-09 AU AU2008273073A patent/AU2008273073B2/en not_active Ceased
- 2008-07-09 JP JP2010515987A patent/JP2010533169A/ja active Pending
-
2013
- 2013-08-09 JP JP2013167153A patent/JP2014001222A/ja active Pending
Non-Patent Citations (3)
Title |
---|
JPN6012041544; ASEAN Food Journal 12(3), 2003, 137-147 * |
JPN6012041547; Asia Pacific J Clin Nutr 11(Suppl), 2002, S467-S472 * |
JPN6012041550; J Agric Food Chem 50(13), 2002, 3693-3697 * |
Also Published As
Publication number | Publication date |
---|---|
US20110003019A1 (en) | 2011-01-06 |
WO2009008697A4 (en) | 2009-03-05 |
EP2170105A1 (en) | 2010-04-07 |
US8808760B2 (en) | 2014-08-19 |
MY164863A (en) | 2018-01-30 |
EP2170105A4 (en) | 2011-08-24 |
AU2008273073B2 (en) | 2014-04-10 |
AU2008273073A1 (en) | 2009-01-15 |
JP2014001222A (ja) | 2014-01-09 |
WO2009008697A1 (en) | 2009-01-15 |
CN101742928A (zh) | 2010-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010533169A (ja) | ヤシの葉からの抽出物およびその製造方法 | |
KR102589895B1 (ko) | 시나라 카르둔큘러스 및 시트러스 아우란티움 베르가미아의 추출물, 이들의 조합물, 및 이들을 함유하는 제제 | |
KR100372561B1 (ko) | 천연 생약제 추출물을 포함하는 숙취해소용 조성물 및이를 유효성분으로 함유하는 건강보조식품 | |
JPWO2006014028A1 (ja) | サツマイモ茎葉抽出物およびその用途 | |
WO2009051470A1 (en) | Flavour enhancers/food seasoning from seaweeds and a method for producing and uses thereof | |
El-Yamani | Cinnamon, cardamom and ginger impacts as evaluated on hyperglycemic rats | |
WO2009060024A1 (en) | Extract formulation of opuntia ficus indica | |
JP2003192605A (ja) | リパーゼ阻害剤 | |
MX2008012230A (es) | Composicion de extracto de plantas naturales para la prevencion y recuperacion de hiperlipidemia y de trastornos cerebrovasculares, te natural que la contiene como ingrediente activo, y metodo para preparar el te natural. | |
Yang et al. | The nutritional and bioactive components, potential health function and comprehensive utilization of pomegranate: a review | |
Osman | Coconut (Cocos nucifera) oil | |
KR100552398B1 (ko) | 작두콩 추출물을 포함하는 숙취해소용 음료조성물 | |
JP5609834B2 (ja) | リパーゼ阻害剤 | |
WO2002066041A1 (en) | Natural composition | |
JP4486096B2 (ja) | 宿酔解消及び肝機能回復に効果がある天然茶及びその製造方法 | |
JP4979184B2 (ja) | 杜仲葉水抽出成分を含むリパーゼ阻害剤 | |
Singh et al. | Almond (Prunus amygdalus Batsch.): a latest review on pharmacology and medicinal uses | |
JP2013510140A (ja) | 脂肪肝改善剤組成物 | |
Masihuzzaman et al. | Badam shireen (Prunus dulcis Mill): A ghiza-e-dawaee and immunomodulator: A latest review | |
JP2004352626A (ja) | 植物由来成分を含有する抗コレステロール剤 | |
JP5884112B2 (ja) | 筋肉増強剤 | |
JP2010105923A (ja) | アカシア属樹皮由来物を含有するPPARδ発現促進剤 | |
SG184710A1 (en) | Extract from palm leaves and a method for producing the same | |
Mohamed et al. | Kola Nut (Cola nitida (Vent.) Schott & Endl.) Use in Diabetes: Molecular, Cellular, and Metabolic Effects | |
Ragab et al. | Protective effect of Beet Roots and Leaves on Kidney Disorder inGentamicin-Induced Rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110309 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120814 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121113 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121120 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121212 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121219 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130110 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130212 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130409 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130809 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130927 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140909 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140912 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141009 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141028 |